AGT and Hyperkalemia: Compared to ACEIs/ARBs monotherapy, the dual blockade of aliskirien combination therapy cause the more significant decrease in aldosterone due to the more significant blockade of Ang II generation, which should not only account for the superior antihypertension effect, but also the increased incidence of hyperkalemia.